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Abstract
Background: Newer models of palliative and supportive cancer care view the person as an active agent in
managing physical and psychosocial challenges. Therefore, personal efficacy is an integral part of this model. Due
to the lack of instruments in Italian to assess coping self-efficacy, the present study included the translation and
validation of the Italian version of the Cancer Behavior Inventory–Brief (CBI-B/I) and an initial analysis of the utility of
self-efficacy for coping in an Italian sample of palliative care patients.
Methods: 216 advanced cancer patients who attended palliative care clinics were enrolled. The CBI-B/I was
administered along with the European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 (EORTC QLQ-C30), the Mini Mental Adjustment to Cancer Scale (Mini-MAC), the Cancer
Concerns Checklist (CCL), and the Hospital Anxiety and Depression Scale (HADS). The Eastern Cooperative Oncology
Group Performance Status (ECOG-PS) ratings of functional capacity were completed by physicians.
Results: Factor analysis confirmed that the structure of the CBI-B/I was consistent with the English version. Internal
consistency reliability and significant correlations with the EORTC QLQ-C30, Mini-MAC, and HADS supported the
concurrent validity of the CBI-B/I. Differences in CBI-B/I scores for high versus low levels of the CCL and ECOG-PS
supported the clinical utility of the CBI-B/I.
Conclusions: The CBI-B/I has strong psychometric properties and represents an important addition to newer model
of palliative and supportive care. In order to improve clinical practice, the CBI-B/I could be useful in identifying
specific self-efficacy goals for coping in structured psychosocial interventions.
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Background
Self-efficacy theory has a long history of guiding assess-
ment and interventions in many health domains [1–4],
including cancer [5]. Generally, greater self-efficacy for
coping has been positively associated with adjustment to
cancer, quality of life (QOL), positive mood, and treat-
ment seeking [5–7] and negatively correlated with can-
cer symptoms [8, 9]. There is an increasing interest in
the role of self-efficacy with regard to patients with ad-
vanced cancer and those in palliative and supportive
care, that is, those who have incurable cancer and may
not be receiving medical treatment to extend life.
The evidence for the importance of self-efficacy for
coping in the context of palliative and supportive care is
connected to its relationship with not only self-care but
also with adjustment and quality of life. For example,
Baile, Palmer, Bruera, & Parker [10] found negative cor-
relations between number of concerns (e.g., needing
more information about illness/treatment, not being able
to do usual activities, caring for self ) and coping
self-efficacy in palliative care patients. In patients with
advanced disease, cancer self-efficacy expectations,
which included coping self-efficacy, activities of daily liv-
ing (ADL) efficacy, and affect regulation self-efficacy,
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mediated the relationship between functional status and
emotional well-being, thus mitigating the negative ef-
fects of physical limitations on emotional well-being
[11]. Similarly, a mediating effect of coping self-efficacy
in the relationship between symptoms and depression
was also found in a sample of cancer survivors who were
on the average 9.3 years post diagnosis [12].
In order to assess the utility of coping self-efficacy in
palliative and supportive care, it is critical to have estab-
lished measures with good psychometric properties. One
option is to develop measures that are specifically re-
lated to coping in particular phases of cancer (e.g., diag-
nosis, transition to survivorship, etc.). Another approach
is to test the utility of measures used in all phases of
care. Thus, measures of self-efficacy expectations for
coping, which have been useful in assessing patients and
survivors [5, 13] may also be useful for assessing those
in palliative and supportive care in terms of the relation-
ship between coping and quality of life.
In line with self-efficacy theory and supporting the
need for self-efficacy-based assessments are emerging
models of care for persons receiving palliative and sup-
portive care [14]. In those models, people are not viewed
as passive recipients of care but as active agents in terms
of negotiating the challenges that they confront. There-
fore, the concept of personal efficacy [15], particularly
self-efficacy for coping, is an integral part of this new
model of palliative care and, in addition, that sense of
agency can be cast in the context of a general model of
self-regulation [16]. That is, the process of
self-regulation including having goals, making plans to
reach those goals, and coping with the challenges that
arise in the process are all-important aspects of quality
of life in palliative and supportive care.
The challenges that advanced cancer patients may face
in palliative care include dealing with severe symptoms
of pain and fatigue, and having the functional capacity to
manage their lives independently. Also, patients receiv-
ing palliative and supportive care may have more basic,
proximal and short-term QOL goals involving specific
physical and emotional challenges [17]. For example, de-
pression represents the most common mental health
problem in advanced cancer and palliative care [18] add-
ing a significant burden to this population [19]. In
addition, there are challenges in patient care with regard
the difficulty patients and physicians face in engaging in
discourse about dying and death [20] and providing care
that respects the dignity of the person receiving it [21].
In the context of these physical and emotional chal-
lenges to the quality of life and the complexities inherent
in relationships with health care providers, emerging
model of palliative care in which patients are viewed as
active agents in their self-care, self-efficacy expectations
for particular coping behaviors are critical in striving
toward QOL goals. Thus, it becomes important not only
to conceptualize this emerging model of palliative and
supportive care but also to be able to accurately assess
and empirically describe patients in terms of this new
model. Finally, this assessment process should have clin-
ical utility for developing interventions for those who
are struggling with poor quality of life and who may not
easily adopt the personal agency model in palliative care.
The Cancer Behavior Inventory–Brief (CBI-B) version
[5], derived from the original, longer 33-item version
[13], represents a comprehensive and efficient brief
measure of self-efficacy for coping with cancer that
could be easily used as a patient-reported outcome
measure in a palliative care clinical setting. Unlike other
measures of self-efficacy for coping such as by Lev et al.
[22], the CBI-B has a stable factor structure across vari-
ous types of cancer as well as established psychometric
qualities. Compared to a measure by Telch & Telch [23],
which lacks information on its construction and psycho-
metric analyses and has not been subjected to peer re-
view nor published, the development of the CBI-B was
clearly presented and subjected to the rigors of the pub-
lication process. The CBI-B is also much briefer than
those measures and, therefore more useful in clinical re-
search settings. Therefore, the first aim of this study was
to use standard methodology to translate the CBI-B into
Italian and then to confirm the structure and psycho-
metric quality of an Italian version of the Cancer Behav-
ior Inventory–Brief (CBI-B/I) in palliative care. The
second aim was to advance the research [6, 24] on clin-
ical utility of CBI-B/I in an Italian sample of palliative
care patients by investigating scores on the CBI-B/I in
relation to other measures that are important in the con-
text of palliative and supportive care and represent tar-
gets of interventions to improve patients’ quality of life.
Methods
Translation of the Cancer behavior inventory-brief/Italian
The CBI-B/I is a measure of self-efficacy for coping in cancer
patients. The instrument consists of 12 items (rated 1 = not
at all confident to 7 = totally confident) and was derived from
the longer version of the CBI [13]. As in the CBI-B English
version [5], the individual items are summed to yield 4 scales
(“Coping and stress management” - 3 items, “Maintaining in-
dependence” - 4 items, “Managing affect” - 3 items, and
“Participating in medical care” - 2 items) and a total score or
composite index. The translation of the CBI-B followed for-
ward and backward translations of the original scale, follow-
ing the EORTC translation guidelines [25]. Two Italian
translators independently completed the forward translation
and negotiated any differences in the two versions. The rec-
onciled Italian version was then given to two English transla-
tors, who independently back-translated the measure. Any
discrepancies were discussed and resolved, and modifications
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were made in the CBI-B/I to take into account any reword-
ing to improve the conceptual relevance and comprehension
of the items. Finally, a small focus group of 5 patients was
convened, the resulting Italian CBI-B/I was administered,
and based on the discussion of each item, final and minor
modifications were made.
Validation procedure
This study took place in three Italian cancer centers:
Padua, Bassano del Grappa (Vicenza), and Naples. The
sample consisted of a consecutive series of patients at-
tending the Oncology Outpatient clinics for symptom
control and palliative care. Criteria for inclusion were:
age ≥ 18 years, a diagnosis of advanced cancer in which
any treatment that was being administered had no cura-
tive intent, and the ability to speak and read Italian flu-
ently. Patients were excluded from treating clinicians if
they displayed any signs of cognitive impairment or had
such poor functional capacity that they could not par-
ticipate in the interview portion of the study.
Upon arrival to outpatient oncology clinics, patients
were asked if they would be interested in participating in
a research project. If they agreed, the study was ex-
plained to them, and informed consent as well as per-
mission to obtain specific information from the
participants’ medical record, were obtained. Following
informed consent, the participants were interviewed in-
dividually in a private room by the researcher obtaining
socio-demographic information such as age, gender,
marital status, education, occupation, religious practices.
Then participants were asked to complete a survey that
contained the following instruments: the CBI-B/I, the
EORTC QLQ-C30, the Mini-MAC, the HADS Scale, the
CCL, and a short debriefing questionnaire to define pa-
tient acceptability and understanding.
Measures
Concerns checklist (CCL)
The CCL [10] is a 15-item survey that is used in pallia-
tive and supportive care in which patients rate the de-
gree of concern on a “0” (not at all) to “3” (very much)
scale. Eleven items are listed (e.g., worries or concerns
about the future, caring for yourself, the way doctors
and nurses communicate with you) and 4 items have
space for the participant to name additional concerns
and rate them. The score for this study consisted of the
sum of the ratings of the first 11 concerns.
Mini mental adjustment to Cancer scale (Mini-MAC)
The Mini-MAC [26, 27] is a 29-item instrument that
evaluates cognitive and behavioral responses to cancer.
The factors of the Mini-MAC are: Fighting Spirit, Hope-
lessness, Anxious Preoccupation, Fatalism, and Cognitive
Avoidance. Each item is rated on a 4-point scale that
ranges from “definitely does not apply to me” to “defin-
itely applies to me”. Cronbach’s alphas for each scale
have ranged from 0.62–0.88 [28].
Hospital anxiety and depression scale (HADS)
The HADS [29] is a 14-item self-report measure de-
signed to assess depression and anxiety. Respondents are
asked to rate each statement in considering the previous
week on a 0–4 scale that taps into frequency. Internal
consistency values for the current study were 0.85 for
the depression scale, 0.83 for the anxiety scale, and 0.89
for the total scale.
European Organization for Research and Treatment of
Cancer quality of life questionnaire-Core 30 (EORTC QLQ-
C30)
The EORTC QLQ-C30 [30] includes 30 items that are
rated on a 4-point scale that ranges from “not at all” to
“very much”. The EORTC QLQ-C30 has a global score,
5 functional scales (physical, role, emotional, cognitive
and social), 3 symptoms scales (fatigue, nausea/vomiting,
pain), and 6 single items (dyspnea, insomnia, appetite
loss, constipation, diarrhea and financial difficulties). For
the global score and the functional scales of an Italian
version of the EORTC QLQ-C30 [31], internal
consistency ranged from 0.64–0.90; alphas were 0.85 for
fatigue, 0.82 for pain and 0.54 for nausea/vomiting.
Eastern cooperative oncology group performance status
(ECOG-PS)
ECOG-PS ratings were obtained from the medical re-
cords with the participants’ written permission. The
ECOG-PS ratings range from “0” Fully active, able to
carry on all pre-disease performance without restriction
to “5” Dead. There is evidence that reliability of descrip-
tion is quite high when dividing patients into two
groups: low (0–2) versus high [3, 4] [32].
Socio-demographic and medical data
Socio-demographic data were obtained from patients via
an interview. Medical data obtained from the partici-
pants’ medical records included the following:
ECOG-PS, diagnosis, and treatments.
Statistical analyses
The sample size was based on the ability to verify an ad-
equate fit of CBI-B/I to the hypothesized four-factor
model of the English version [5], with 12 manifest vari-
ables. Using the root-mean-square error of approxima-
tion (RMSEA) as the measure of model fit, a minimum
of 210 patients provides a 90% power level to test
RMSEA≤0.05 when RMSEA = 0.08, using a 0.05 signifi-
cance level [33].
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Clinical and demographic characteristics of patients
were described using median and range for quantitative
data and frequencies and percentages for categorical
data. A confirmatory factor analysis with maximum like-
lihood estimation was carried out to confirm the factor
structure of the CBI-B/I and determine the model fit.
According to Browne and Cudeck [34], a RMSEA value
of < 0.05 is indicative of close fit, between 0.05 and 0.08
fair fit and > 0.10, mediocre fit. We used the
non-normed fit index (NNFI) and the comparative fit
index (CFI) with values > 0.9 as indicative of an accept-
able model. Internal reliability was confirmed by a Cron-
bach alpha value greater than 0.7.
Different levels of measurement invariance were tested
using a structural equation modeling approach; metric,
scalar and strict invariance were verified by comparing
each model with the configural invariance one. A
non-significant difference in chi-squared values and a
difference in CFI and RMSEA < 0.01 were considered as
evidence of measurement invariance.
Concurrent validity was determined by examining the
hypothesis that the higher the self-efficacy the higher the
quality of life of the patients: the EORTC QLQ-C30 glo-
bal score, emotional, role, social and physical functioning
should positively correlate with the four factors and the
composite index of CBI-B/I. The CBI-B/I should nega-
tively correlate with anxious preoccupation (Mini-MAC)
and the HADS questionnaire scales to verify that higher
self-efficacy was indicative of a lower anxiety and de-
pression. To measure concurrent validity Pearson coeffi-
cients were computed.
To test the clinical utility of the CBI-B/I, non-parametric
analyses of variance were used for each dimension to verify
whether the scales could differentiate between patients ac-
cording to their clinical characteristics. Variables of primary
interest were age, gender, spirituality, the CCL and
ECOG-PS. Age was dichotomized at the median,
ECOG-PS was dichotomized as 0–2 (high functioning) or
3–4 (low functioning) based on prior research [32]. Results
were reported with their 95% confidence intervals (CI). All
P values were two-sided, and P value of < 0.05 was consid-
ered statistically significant. Statistical analyses were per-
formed using SAS statistical package (SAS, rel. 9.4; SAS
Institute Inc.)
Results
From June 2012 to July 2014, 216 advanced cancer pa-
tients were enrolled from 3 centers in Italy. Among
them (median age: 60.2 years; range: 35–86), the most
prevalent diagnosis was breast cancer (44.4%); the time
since diagnosis was < 1 year for 28.7%, 1–5 years for
43.5%, > 5 years for 27.8% of patients; 143 (66.2%) were
female, 77% married, and, for most patients (199, 92.1%),
the ECOG-PS grade was 0–2 (Table 1).
Patients reported that the CBI-B/I was brief and clear,
most of them (89%) took less than 10min to complete
the questionnaire and less than 4% found some question
confusing, upsetting or irrelevant.
One hundred and ninety six patients answered all
items (90.7%) and only three patients missed more than
two items (1.4%). Missing data were more frequent for
item 12 that is inherent to the management of nausea
and vomiting (10 patients).
Confirmatory factor analysis and reliability
The hypothesized four-factor model yields a 90% confi-
dence limit for the RMSEA with bounds of 0.06 and
0.100, providing support for a fair fit. The CFI = 0.93 and
NNFI = 0.91 met all the required criteria to support the
goodness of fit (Fig. 1). The paths between the items and
the factors, measured by the loadings, were all statisti-
cally significant, ranging from 0.58 to 0.94, with only
two slightly below 0.60, indicating that all items contrib-
uted to measurement of the underlying latent factor with
a proportion of explained variance of at least 34%.
Considering the Cronbach reliability estimates for each
factor (0.72 for “Coping stress management”, 0.83 for
“Maintaining independence”, 0.69 for “Managing affect”
and 0.75 for “Participating medical care”) only “Managing
affect” was marginally below the 0.70. Importantly, the in-
ternal consistency for the composite CBI-B/I score was
Table 1 Clinical and demographic characteristics of patients
Frequency Percentage
Age Median (range) 62 (35–86)
Gender Female 143 66.2
Male 73 33.8
Marital status Unmarried 46 22.0
Married 163 78.0
Missing 7
Education Primary/Secondary
school
122 60.4
High school/University 80 39.6
Missing 14
ECOG Performance
Status
0–2 199 92.6
3–4 16 7.4
Cancer site Breast 96 44.4
Lung 27 12.5
Digestive/
Gastrointestinal
51 23.6
Other 42 19.4
Time since diagnosis < 1 year 60 28.7
1–5 years 91 43.5
> 5 years 58 27.7
Missing 7
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0.86. Finally, correlation between factors, which were all
significant, ranged from 0.43 to 0.68, indicating a moder-
ate relationship among these constructs.
Configural invariance
The model structure was invariant across sex, with all
factor loadings statistically significant and an RMSEA of
0.09 (90% CI: 0.07–0.11), indicating that male and fe-
male patients conceptualize the construct in the same
way. Comparisons to test the metric invariance, scalar
invariance and strict invariance are reported in Table 2.
All chi-squared tests were not significant and the differ-
ence in CFI and RMSEA between each model and the
configural invariance model were < 0.01. These data indi-
cated that the magnitude of loadings, intercepts and
residual variances was similar across groups, thus con-
firming invariance as a function of participant sex.
Demographic analyses
There were no significant correlations between the
CBI-B/I and the most of socio-demographic data (i.e.,
sex, time since diagnosis, marital status, spirituality). Re-
garding age, we found that older patients (> 62 years old)
reported higher self-efficacy than patients with less than
62 (p = 0.0225), which was consistent with other versions
of the CBI [13]. The non-significant effects for most cor-
relation of the CBI-B/I and demographic variables is im-
portant in supporting the clinical utility of the CBI-B/I
in that the only moderator variable to consider in asses-
sing coping self-efficacy is age.
Concurrent validity
Concurrent validity was tested by examining the signifi-
cance of correlation coefficients between the CBI-B/I
and measures of quality of life (EORTC QLQ-C30), re-
sponses to cancer (Mini-MAC), and distress (HADS)
(Table 3). The four factors and the composite index of
CBI-B/I were positively correlated with overall quality of
life, as well as emotional, role, social and physical func-
tioning. With respect to the Mini-MAC, the four factors
and the composite index of CBI-B/I were positively cor-
related with Fighting Spirit, Fatalism, and Cognitive
Avoidance and negatively correlated with Hopelessness,
and Anxious Preoccupation. The four factors and the
composite index of CBI-B/I were negatively correlated
with the Anxiety and Depression scales of the HADS.
Finally, the composite CBI-B/I was negatively correlated
with the CCL (r = − 0.30). The direction and significance
of these coefficients confirmed the validity of the CBI-B/I.
Clinical utility of the CBI-B/I for supportive and palliative
care
The clinical utility of the CBI-B/I was investigated by
comparing the composite CBI-B/I score at high and low
levels on the CCL and the ECOG-PS. Because this utility
analysis is based on different methods of assessment
(CCL: self-report, ECOG-PS: physicians’ ratings), the
convergence of findings from these two measures would
augment concurrent validity as well as provide evidence
for the clinical utility of the CBI-B/I. The mean differ-
ences on the composite CBI-B/I index were computed
Fig. 1 Path diagram of the four-factor structural equation model for
the Italian version of the Cancer Behavior Inventory-Brief (CBI-B/I)
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for those patients who, on the CCL, reported 3 or less
concerns compared those who reported more than 3.
Those with less concerns reported significantly higher
efficacy scores. Similar to the CCL, those with higher
functional status (ECOG-PS: 0–2) reported significantly
higher coping efficacy (Table 4). The convergence of the
results for both the CCL and the ECOG-PS contributes
to the potential clinical utility of the CBI-B/I for use in
palliative and supportive care.
Discussion
The aim of the present study was to translate and con-
firm the structure, psychometric quality, and the utility
in palliative care of the Italian version of the CBI-B.
The cross-cultural adaption of the CBI-B/I did not
present any particular problem during the translation
process of the concepts from English to Italian lan-
guage. The translation procedure was linear and the
translated version resulted simple, well-interpreted
and easy to complete. No ambiguous terms or dis-
crepancies between the two versions were identified
and the only item with some missing answers was re-
lated to the management of nausea and vomiting,
probably due to the absence of this symptoms. The
translation techniques reveal an adequate conceptual
equivalence and a good level of comprehensibility.
Our analyses revealed that the CBI-B/I had the same
structure as the original English version [5], was reliable,
valid, and has clinical utility.
The composite index of CBI-B/I was positively corre-
lated with the overall quality of life, as well as the
EORTC QLQ-C30 subscales that measure physical,
emotional, role, and social functioning: these results
demonstrate that palliative care patients with higher
scores on self-efficacy for coping with cancer also have
better quality of life. Moreover, the significant negative
correlations of CBI-B/I composite index with the fol-
lowing EORTC QLQ-C30 symptom subscales -fatigue,
pain, dyspnea, and appetite loss– highlighted an important
relationship between self-efficacy for coping and symptom
management. Considering the cross-sectional design of
our study, we cannot infer the directional causation.
Therefore, an implication of these quality of life findings
could suggest that reducing symptoms could lead to im-
proving coping but also that interventions to improve
coping efficacy may affect symptom management. This
should be tested in a longitudinal design.
As hypothesized, the CBI-B/I was negatively correlated
with CCL, which is a proxy for emotional distress [10]
and corroborates the negative relationship between the
CBI-B/I and HADS, which assesses anxiety and depres-
sion. These results are similar to the English version of
the CBI-B [5] and furthermore, reinforce the parallel be-
tween the English and the Italian versions.
Consistent with recent studies [28], we found that
the CBI-B/I was positively correlated with Fighting
Spirit, Cognitive Avoidance and Fatalism. This may
indicate that, where the options for treatment to cure
the disease may not be forthcoming, distraction and
not thinking about one’s illness can alleviate emo-
tional distress. In fact, distraction is widely recognized
as emotion-focused coping strategy [35] for the po-
tential to diverts the focus of the attention from
negative to positive thoughts. Furthermore, in some
current literature, there seem to be cultural differences emer-
ging regarding the role of an avoidant coping response. In
the Chinese, Korean as well as the Greek and Italian versions
of the Mini-MAC, Cognitive Avoidance is considered to be
an indicator of positive adjustment [26, 36–38], whereas in
the Norwegian and English versions, Cognitive Avoidance
appears to be an indicator of poor adjustment [27, 39].
Similarly, Grassi et al. [26] found that Fatalism and Cognitive
Avoidance in Spanish and Portuguese cancer patients repre-
sented adaptive coping strategies.
Thus, although Fatalism was originally identified as a
stoic acceptance response [40] representing maladaptive
coping [41], there are some aspects of this coping
method that may signify acceptance of advanced disease
Table 2 Measurement invariance analysis
χ2 DF p-value CFI RMSEA
Configural Invariance Female 96.14 48 0.93 0.09
Male 75.86 48 0.90 0.09
Both 172.00 96 0.92 0.09
Metric invariance 187.28 108 0.91 0.09
(equal loadings) Δ 15.28 12 0.2263 0.004 0.003
Scalar invariance 191.21 116 0.92 0.08
(equal loadings+intercepts) Δ 3.93 8 0.8634 0.005 0.005
Strict invariance 207.00 128 0.92 0.08
(equal loadings+intercepts+residuals) Δ 15.78 12 0.2014 0.004 0.002
Serpentini et al. BMC Palliative Care           (2019) 18:34 Page 6 of 9
and could potentially be adaptive [40, 42], particularly in
palliative care. Along those lines, recent analyses by the
authors of the original MAC scale have shown that a more
general scale of positive adjustment, in fact, included
items from both the Fighting Spirit and Fatalism scales
[40, 42]. Thus, the modestly positive correlation between
the CBI-B/I and Fatalism may be understandable in the
context of palliative and supportive care, in that the items
Table 3 Concurrent validity: Correlation of the Italian version of the Cancer Behavior Inventory-Brief (CBI-B/I) with the EORTC Quality of
Life Questionnaire (QLQ-C30), the Cancer Concerns Checklist (CCL), the Mini Mental Adjustment to Cancer Scale (Mini-MAC) and the
Hospital Anxiety and Depression Scale (HADS)
CBI-B/I
Composite Index Maintaining Independence Managing Affect Participating Medical Care Coping Stress Management
EORTC QLQ-C30
Global Index 0.26 0.28 0.19 0.17 0.20
p-value <.0001 <.0001 0.0047 0.0106 0.0037
Emotional Functioning 0.36 0.36 0.21 0.26 0.35
p-value <.0001 <.0001 0.0027 0.0001 <.0001
Role Functioning 0.27 0.31 0.15 0.21 0.205
p-value 0.0001 <.0001 0.0238 0.0022 0.003
Social Functioning 0.29 0.20 0.24 0.26 0.305
p-value <.0001 0.0031 0.0004 0.0001 <.0001
Physical Functioning 0.24 0.29 0.10 0.15 0.235
p-value 0.0005 <.0001 0.13 0.0251 0.0006
Fatigue −0.23 −0.26 −0.08 −0.20 −0.24
p-value 0.0008 0.0001 0.2766 0.0032 0.0005
Pain −0.14 − 0.17 − 0.05 − 0.12 − 0.10
p-value 0.0410 0.0127 0.4830 0.0840 0.1287
Dyspnea −0.19 − 0.12 − 0.10 −0.22 − 0.22
p-value 0.0055 0.0816 0.1459 0.0011 0.0013
Appetite loss −0.21 − 0.24 − 0.02 −0.22 − 0.21
p-value 0.0025 0.0003 0.7016 0.0014 0.0025
CCL −0.30 −0.24 − 0.18 −0.25 − 0.36
p-value <.0001 0.0005 0.0069 0.0002 <.0001
Mini-MAC
Fighting Spirit 0.42 0.38 0.28 0.30 0.315
p-value <.0001 <.0001 <.0001 <.0001 <.0001
Hopelessness −0.46 −0.47 −0.31 −0.30 −0.32
p-value <.0001 <.0001 <.0001 <.0001 <.0001
Fatalism 0.23 0.08 0.19 0.22 0.27
p-value 0.0006 0.2519 0.0055 0.0013 <.0001
Anxious Preoccupation −0.29 −0.25 −0.24 −0.19 −0.28
p-value <.0001 0.0002 0.0004 0.0058 <.0001
Cognitive Avoidance 0.22 0.10 0.14 0.20 0.21
p-value 0.0012 0.1343 0.0445 0.0029 0.0018
HADS
Anxiety −0.40 −0.38 −0.23 −0.26 −0.42
p-value <.0001 <.0001 0.0008 0.0002 <.0001
Depression −0.46 −0.51 −0.30 − 0.25 −0.30
p-value <.0001 <.0001 <.0001 0.0003 <.0001
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in the Fatalism scale express a sense of “letting go” [43],
and benefit finding [44], which may relieve anxiety and
stress.
The second aim of the present study was to establish
the utility of self-efficacy for coping by investigating the
relationship of self-efficacy with constructs that are im-
portant in the context of palliative and supportive care.
Whereas the data are preliminary, it does appear, with
respect to patient-reported concerns (CCL) and
physician-reported functional status (ECOG-PS), that
there is a convergence of the relationship of clinically
relevant issues and functioning, as represented by the
CBI-B/I. The potential utility of the CBI-B/I as a clinical
assessment measure is bolstered by these findings, but
more work is needed in randomized clinical trials and
longitudinal research to firmly establish the clinical util-
ity of the CBI-B/I.
There are limitations that also might be the spring-
board for future work. Firstly, the cross-sectional nature
of the study with only one point in time allows only
comments on our results in terms of association and not
causality. Also, the sample had a large number of female
breast cancer patients, and because of the size, analyses
could not be conducted taking into account type of can-
cer. Future studies could conduct analyses within diag-
noses including measurement invariance as a function of
type of cancer.
Conclusions
In emerging models of palliative and supportive care,
patients are encouraged to be active agents in their
medical care. From this perspective, personal self-effi-
cacy for coping represents a key concept in the man-
agement of the quality of life of patients. In order to
improve clinical practice in supportive and palliative
care, it would be useful to identify the specific level
of self-efficacy for coping in patients receiving pallia-
tive care that could be considered clinically critical.
This could be an important resource both in the
identification of patients’ adaptation process and in
structuring specific psychosocial interventions that are
personalized and tailored. Because self-efficacy is a
specific mutable factor [15] that can be facilitated
with specific psychosocial treatments, it can become a
focal point of interventions. Thus, high quality mea-
sures like the CBI-B/I are critical in the development
and implementation of those interventions in emer-
ging models of palliative and supportive care. This re-
search contributes to those new directions.
Abbreviations
ADL: Activities of Daily Living; CBI-B: Cancer Behavior Inventory-Brief; CBI-B/
I: Italian version of Cancer Behavior Inventory-Brief; CCL: Cancer Concerns
Checklist; CFI: Comparative Fit Index; CI: Confidence Intervals; ECOG-
PS: Eastern Cooperative Oncology Group Performance Status;
EORTC: European Organization for Research and Treatment of Cancer Quality
of Life Questionnaire; HADS: Hospital Anxiety and Depression Scale; Mini-
MAC: Mini Mental Adjustment to Cancer Scale; NNFI: Non-Normed Fit Index;
QLQ-C30: Quality of Life Questionnaire-Core 30; QOL: Quality of Life;
RMSEA: Root-Mean-Square Error of Approximation
Acknowledgements
The authors would like to thank the patients who participated in this study
as well as the physicians and staff of the three cancer centers involved.
Funding
No funding to declare.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
SS, PDB were responsible for the study concept, design and the analysis
plan. SS, AC, TVM, FL conducted a literature review. SS, AC, RM were involved
in data collection. PDB carried out the statistical analysis. SS, PDB, TVM
analyzed and interpreted the data, drafted the manuscript. SS, GLDS, LT, EC
supervised the study. All the authors read and approved the final
manuscript.
Ethics approval and consent to participate
The study was approved by the IOV – IRCCS Research Ethics Committee
(protocol no. 12584/2012), all procedures were in accordance with the 1964
Helsinki declaration and its later amendments, and all patients signed
informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Table 4 Clinical Utility Analyses of the Italian version of the Cancer Behavior Inventory-Brief (CBI-B/I) using the Cancer Concerns Checklist
(CCL) and the ECOG Performance Status (ECOG-PS)
CBI-B/I Composite Index
N Mean SD Median Lower Quartile Upper Quartile p-value
CCL ≤3 concerns 32 83.66 15.97 84.00 76.50 95.50 0.0013
> 3 concerns 180 73.46 16.66 77.50 61.50 85.50
ECOG-PS 0–2 199 75.69 16.66 78.00 63.00 87.00 0.0551
3–4 16 65.06 19.80 65.00 50.50 83.00
Serpentini et al. BMC Palliative Care           (2019) 18:34 Page 8 of 9
Author details
1Istituto Oncologico Veneto IOV – IRCCS, Via Gattamelata, 64, 35128 Padova,
Italy. 2“La Sapienza” University, Rome, Italy. 3University of Notre Dame, South
Bend, Indiana, USA.
Received: 9 May 2018 Accepted: 27 March 2019
References
1. Baldwin AS, Rothman AJ, Hertel AW, Linde JA, Jeffery RW, Finch EA, et al.
Specifying the determinants of the initiation and maintenance of behavior
change: an examination of self-efficacy, satisfaction, and smoking cessation.
Health Psychol. 2006;25(5):626–34.
2. Benight CC, Bandura A. Social cognitive theory of posttraumatic recovery:
the role of perceived self-efficacy. Behav Res Ther. 2004;42(10):1129–48.
3. Manning MM, Wright TL. Self-efficacy expectancies, outcome expectancies,
and the persistence of pain control in childbirth. J Pers Soc Psychol. 1983;
45(2):421–31.
4. Marks R, Allegrante JP, Lorig K. A review and synthesis of research evidence
for self-efficacy-enhancing interventions for reducing chronic disability:
implications for health education practice (part II). Health Promot Pract.
2005;6(2):148–56.
5. Heitzmann CA, Merluzzi TV, Jean-Pierre P, Roscoe JA, Kirsh KL, Passik SD.
Assessing self-efficacy for coping with cancer: development and
psychometric analysis of the brief version of the Cancer behavior inventory
(CBI-B). Psychooncology. 2011;20(3):302–12.
6. Chirico A, Lucidi F, Merluzzi T, Alivernini F, Laurentiis M, Botti G, et al. A
meta-analytic review of the relationship of cancer coping self-efficacy with
distress and quality of life. Oncotarget. 2017;8(22):36800–11.
7. Hirai K, Arai H, Tokoro A, Naka N. Self-efficacy, psychological adjustment and
decisional-balance regarding decision making for outpatient chemotherapy
in Japanese advanced lung cancer. Psychol Health. 2009;24(2):149–60.
8. Mystakidou K, Tsilika E, Parpa E, Panagiotou I, Galanos A, Gouliamos A. Differences
in levels of self-efficacy and anxiety between cancer and chronically-ill patients
attending a palliative care unit. J BUON. 2012;17(4):785–90.
9. Porter LS, Keefe FJ, Garst J, McBride CM, Baucom D. Self-efficacy for
managing pain, symptoms, and function in patients with lung cancer and
their informal caregivers: associations with symptoms and distress. Pain.
2008;137(2):306–15.
10. Baile WF, Palmer JL, Bruera E, Parker PA. Assessment of palliative care cancer
patients' most important concerns. Support Care Cancer. 2011;19(4):475–81.
11. Hirai K, Suzuki Y, Tsuneto S, Ikenaga M, Hosaka T, Kashiwagi T. A structural
model of the relationships among self-efficacy, psychological adjustment,
and physical condition in Japanese advanced cancer patients.
Psychooncology. 2002;11(3):221–9.
12. Philip EJ, Merluzzi TV, Zhang Z, Heitzmann CA. Depression and cancer
survivorship: importance of coping self-efficacy in post-treatment survivors.
Psychooncology. 2013;22(5):987–94.
13. Merluzzi TV, Nairn RC, Hegde K, Martinez Sanchez MA, Dunn L. Self-efficacy
for coping with cancer: revision of the Cancer behavior inventory (version 2.
0). Psychooncology. 2001;10(3):206–17.
14. Bruera E, Hui D. Integrating supportive and palliative care in the trajectory
of cancer: establishing goals and models of care. J Clin Oncol. 2010;28(25):
4013–7.
15. Bandura A. Self-efficacy: The exercise of control. New York1997.
16. Carver CS, Scheier MF. On the self-regulation of behaviour. Cambridge
University Press, New York1998.
17. Hannon B, Swami N, Pope A, Rodin G, Dougherty E, Mak E, et al. The
oncology palliative care clinic at the Princess Margaret Cancer Centre: an
early intervention model for patients with advanced cancer. Support Care
Cancer. 2015;23(4):1073–80.
18. Okuyama T, Akechi T, Mackenzie L, Furukawa TA. Psychotherapy for
depression among advanced, incurable cancer patients: a systematic review
and meta-analysis. Cancer Treat Rev. 2017;56:16–27.
19. Feldstain A, Lebel S, Chasen MR. An interdisciplinary palliative rehabilitation
intervention bolstering general self-efficacy to attenuate symptoms of
depression in patients living with advanced cancer. Support Care Cancer.
2016;24(1):109–17.
20. Wildfeuer J, Schnell MWS. Christian. Talking about dying and death: on new
discursive constructions of a formerly postulated taboo. Discourse Soc.
2015;26(3):366–90.
21. Chochinov HM. Dignity-conserving care--a new model for palliative care:
helping the patient feel valued. JAMA. 2002;287(17):2253–60.
22. Lev EL, Eller LS, Kolassa J, Gejerman G, Colella J, Lane P, et al. Exploratory
factor analysis: strategies used by patients to promote health. World J Urol.
2007;25(1):87–93.
23. Telch CF, Telch MJ. Group coping skills instruction and supportive group
therapy for cancer patients: a comparison of strategies. J Consult Clin
Psychol. 1986;54(6):802–8.
24. Chirico A, Serpentini S, Merluzzi T, Mallia L, Del Bianco P, Martino R, et al.
Self-efficacy for coping moderates the effects of distress on quality of life in
palliative Cancer care. Anticancer Res. 2017;37(4):1609–15.
25. Dewolf L, Koller M, Velikova G, Johnson C, Scott N, Bottomley AEORTC.
Quality of life group translation procedure. 3rd ed. Brussels, Belgium: EORTC
quality of life. Group. 2009.
26. Grassi L, Buda P, Cavana L, Annunziata MA, Torta R, Varetto A. Styles of
coping with cancer: the Italian version of the Mini-mental adjustment to
Cancer (Mini-MAC) scale. Psychooncology. 2005;14(2):115–24.
27. Watson M, Law MG, dos santos M, Greer S, Baruch JMB, Bliss J. The Mini-
MAC: further development of the mental adjustment to Cancer scale. J
Psychosoc Oncol. 1994;12(3):33–46.
28. Zucca AC, Boyes AW, Lecathelinais C, Girgis A. Life is precious and I'm
making the best of it: coping strategies of long-term cancer survivors.
Psychooncology. 2010;19(12):1268–76.
29. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta
Psychiatr Scand. 1983;67(6):361–70.
30. Aaronson NK, Bullinger M, Ahmedzai S. A modular approach to quality-of-
life assessment in cancer clinical trials. Recent Results Cancer Res. 1988;111:
231–49.
31. Apolone G, Filiberti A, Cifani S, Ruggiata R, Mosconi P. Evaluation of the
EORTC QLQ-C30 questionnaire: a comparison with SF-36 health survey in a
cohort of Italian long-survival cancer patients. Ann Oncol. 1998;9(5):549–57.
32. Sørensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment
in cancer patients. An inter-observer variability study. Br J Cancer. 1993;67(4):
773–5.
33. MacCallum R, Browne M, Sugawara H. Power analysis and determination of
sample size for covariance structure modeling. Psychol Methods. 1996;1(2):
130–49.
34. Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Newbury
Park CS, editor. Testing structural equation models. Newbury Park, CA:
Sage1993. p. 136–62.
35. Lazarus RS, Folkman S. Stress, appraisal, and coping: springer publishing co
Inc; 1984.
36. Anagnostopoulos F, Kolokotroni P, Spanea E, Chryssochoou M. The Mini-
mental adjustment to Cancer (Mini-MAC) scale: construct validation with a
Greek sample of breast cancer patients. Psychooncology. 2006;15(1):79–89.
37. Ho SM, Fung WK, Chan CL, Watson M, Tsui YK. Psychometric properties of
the Chinese version of the Mini-mental adjustment to Cancer (MINI-MAC)
scale. Psychooncology. 2003;12(6):547–56.
38. Kang JI, Chung HC, Kim SJ, Choi HJ, Ahn JB, Jeung HC, et al. Standardization of
the Korean version of Mini-mental adjustment to Cancer (K-Mini-MAC) scale:
factor structure, reliability and validity. Psychooncology. 2008;17(6):592–7.
39. Bredal IS. The Norwegian version of the Mini-mental adjustment to Cancer
scale: factor structure and psychometric properties. Psychooncology. 2010;
19(2):216–21.
40. Watson M, Greer S, Young J, Inayat Q, Burgess C, Robertson B. Development
of a questionnaire measure of adjustment to cancer: the MAC scale. Psychol
Med. 1988;18(1):203–9.
41. Goodwin L, Price A, Lee W, Rayner L, Moorey S, Monroe B, et al. I've had a
good life, what's left is a bonus: factor analysis of the mental adjustment to
Cancer scale in a palliative care population. Palliat Med. 2014;28(3):243–55.
42. Watson M, Homewood J. Mental adjustment to Cancer scale: psychometric
properties in a large cancer cohort. Psychooncology. 2008;17(11):1146–51.
43. Serpentini S, Capovilla E, Merluzzi TV. Lasciare andare: Potenzialità di
applicazione in psiconcologia e nelle cure palliative. ("Letting go": potential
application in psycho-oncology and palliative care): Mosciano, S.A., Italy,
Artemia Edizioni; 2016.
44. Sears SR, Stanton AL, Danoff-Burg S. The yellow brick road and the emerald
city: benefit finding, positive reappraisal coping and posttraumatic growth
in women with early-stage breast cancer. Health Psychol. 2003;22(5):487–97.
Serpentini et al. BMC Palliative Care           (2019) 18:34 Page 9 of 9
